A detailed history of Tower Research Capital LLC (Trc) transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 184 shares of BOLT stock, worth $106. This represents 0.0% of its overall portfolio holdings.

Number of Shares
184
Previous 184 -0.0%
Holding current value
$106
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.73 - $1.5 $3,914 - $8,043
-5,362 Reduced 96.68%
184 $0
Q1 2024

May 15, 2024

SELL
$1.01 - $1.4 $2,716 - $3,765
-2,690 Reduced 32.66%
5,546 $7,000
Q4 2023

Feb 13, 2024

BUY
$0.85 - $1.12 $7,000 - $9,224
8,236 New
8,236 $9,000
Q2 2023

Aug 14, 2023

SELL
$1.27 - $1.95 $4,216 - $6,474
-3,320 Reduced 83.59%
652 $0
Q1 2023

May 09, 2023

BUY
$1.29 - $1.66 $2,263 - $2,913
1,755 Added 79.16%
3,972 $5,000
Q4 2022

Feb 10, 2023

SELL
$1.26 - $1.51 $20,563 - $24,643
-16,320 Reduced 88.04%
2,217 $3,000
Q3 2022

Nov 10, 2022

BUY
$1.48 - $2.61 $15,528 - $27,384
10,492 Added 130.42%
18,537 $28,000
Q2 2022

Aug 15, 2022

BUY
$1.41 - $2.91 $2,779 - $5,735
1,971 Added 32.45%
8,045 $16,000
Q1 2022

May 12, 2022

BUY
$2.74 - $4.82 $4,847 - $8,526
1,769 Added 41.09%
6,074 $17,000
Q4 2021

Feb 14, 2022

BUY
$4.19 - $13.97 $15,159 - $50,543
3,618 Added 526.64%
4,305 $21,000
Q3 2021

Nov 15, 2021

SELL
$11.15 - $18.6 $10,492 - $17,502
-941 Reduced 57.8%
687 $9,000
Q2 2021

Aug 16, 2021

BUY
$15.4 - $31.46 $8,824 - $18,026
573 Added 54.31%
1,628 $25,000
Q1 2021

May 17, 2021

BUY
$25.86 - $39.93 $27,282 - $42,126
1,055 New
1,055 $35,000

Others Institutions Holding BOLT

About Bolt Biotherapeutics, Inc.


  • Ticker BOLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,641,500
  • Market Cap $21.8M
  • Description
  • Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...
More about BOLT
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.